These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 16998496)

  • 1. Clinical management of BRCA1 and BRCA2 mutation carriers.
    Domchek SM; Weber BL
    Oncogene; 2006 Sep; 25(43):5825-31. PubMed ID: 16998496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives in the clinical management of BRCA mutations carriers.
    Savarese A; Cognetti F
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):31-5. PubMed ID: 12585651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers.
    Heisey RE; Carroll JC; Warner E; McCready DR; Goel V
    Can Fam Physician; 1999 Jan; 45():114-24. PubMed ID: 10889864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients.
    Konstantopoulou I; Rampias T; Ladopoulou A; Koutsodontis G; Armaou S; Anagnostopoulos T; Nikolopoulos G; Kamakari S; Nounesis G; Stylianakis A; Karanikiotis C; Razis E; Gogas H; Keramopoulos A; Gaki V; Markopoulos C; Skarlos D; Pandis N; Bei T; Arzimanoglou I; Fountzilas G; Yannoukakos D
    Breast Cancer Res Treat; 2008 Feb; 107(3):431-41. PubMed ID: 17453335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
    Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
    Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
    Roukos DH; Briasoulis E
    Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of BRCA genes in hereditary breast and ovarian cancer.
    Radice P
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):9-12. PubMed ID: 12585647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
    Hartikainen JM; Kataja V; Pirskanen M; Arffman A; Ristonmaa U; Vahteristo P; Ryynänen M; Heinonen S; Kosma VM; Mannermaa A
    Clin Genet; 2007 Oct; 72(4):311-20. PubMed ID: 17850627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk.
    Jernström H; Borg K; Olsson H
    Mol Genet Metab; 2005; 86(1-2):320-7. PubMed ID: 16084122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
    Torres D; Rashid MU; Gil F; Umana A; Ramelli G; Robledo JF; Tawil M; Torregrosa L; Briceno I; Hamann U
    Breast Cancer Res Treat; 2007 Jun; 103(2):225-32. PubMed ID: 17080309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hereditary ovarian cancer--assessing risk and prevention strategies.
    Pavelka JC; Li AJ; Karlan BY
    Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey of preventive measures among BRCA1 mutation carriers from Poland.
    Gronwald J; Byrski T; Huzarski T; Cybulski C; Stawicka M; Szwiec M; Debniak T; Tulman A; Sun P; Oszurek O; Lubinski J; Narod SA
    Clin Genet; 2007 Feb; 71(2):153-7. PubMed ID: 17250664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pros and cons of genetic testing for breast and ovarian cancer risk.
    Frank TS; Braverman AM
    Int J Fertil Womens Med; 1999; 44(3):139-45. PubMed ID: 10435912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland.
    Gronwald J; Byrski T; Huzarski T; Cybulski C; Sun P; Tulman A; Narod SA; Lubinski J
    Breast Cancer Res Treat; 2006 Jan; 95(2):105-9. PubMed ID: 16261399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
    Forman AD; Hall MJ
    Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.